|Bid||6.26 x 200|
|Ask||7.50 x 500|
|Day's Range||6.83 - 7.16|
|52 Week Range||5.77 - 14.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.08|
BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding ENDP is favorable, with net inflows of $15.68 billion.
NEW YORK, March 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
South Dakota on Wednesday sued three major drugmakers, accusing them of deceptively marketing prescription opioids and contributing to a nationwide epidemic. Marty Jackley, the state's attorney general, announced civil claims against Purdue Pharma LP, a unit of Endo International Plc and Johnson & Johnson's Janssen unit. The lawsuit makes South Dakota at least the 16th U.S. state to sue manufacturers over opioids, which can be used to treat pain.
Endo International Plc said on Thursday it had obtained a preliminary injunction preventing privately-held QuVa Pharma Inc from marketing and releasing a compounded drug that could rival its blood pressure shot Vasostrict. The injunction was issued by U.S. District Judge Brian Martinotti in Trenton, New Jersey, to two Endo subsidiaries which are suing QuVa, claiming its compounded product misappropriates trade secrets related to Vasostrict. Endo separately filed a lawsuit against the U.S. Food and Drug Administration (FDA) in October, accusing the agency of improperly authorizing the bulk compounding of hundreds of drugs, including "essentially a copy" of Vasostrict.
Endo Obtains Preliminary Injunction Against QuVa Pharma, Inc. Preventing Marketing and Release of Vasopressin Product
DUBLIN, March 1, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC (Par), have obtained a preliminary injunction preventing QuVa Pharma, Inc. (QuVa) from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict®, the first and only vasopressin injection, USP, product approved by the U.S. Food and Drug Administration. The preliminary injunction, issued today by the Hon. Brian R. Martinotti, U.S. District Judge, is effective through the conclusion of a trial, which has not yet been scheduled. In August 2017, Par filed a complaint against QuVa and several individual defendants in the U.S. District Court for the District of New Jersey (Case No. 17-6115) alleging, among other claims, the misappropriation of Par's trade secrets by the defendants in connection with QuVa's development of a bulk compounded vasopressin product.
Sorrento Therapeutics Inc said on Wednesday the U.S. Food and Drug Administration has approved ZTlido, its non-opioid painkiller patch for nerve pain related to shingles, which it plans to launch later this year. ZTlido, which Sorrento added as part of its 2016 acquisition of majority stake in privately-held SCILEX Pharmaceuticals Inc, was approved for postherpetic neuralgia (PHN), a common complication of shingles that manifests as a burning pain.
Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.
The federal government, backing litigation by states and cities, will seek reimbursement from major drug companies and distributors to recover costs it has borne from the opioid epidemic, the U.S. Justice Department said on Tuesday. Attorney General Jeff Sessions said Washington would side with plaintiffs in the litigation that accuses the drug makers of deceptively marketing opioids and alleges that distributors ignored red flags indicating the painkillers were being diverted for improper uses.
Valeant Pharmaceuticals International (VRX) will report earnings on Wednesday morning, which could be a chance for the pharmaceutical company to turn around its year-to-date losing streak. Analysts are looking for Valeant to earn 97 cents a share in the quarter, down from $1.04 in the third quarter and $1.26 in the fourth-quarter of 2016. The stock has certainly been volatile lately--its down 9.5% in 2018--hit by downgrades that indicate that there's still plenty of skepticism, about the once high-flying specialty pharma company.
Endo International Plc's full-year revenue and profit forecasts fell short of Street estimates, due to continued pressure on its generics business and increased competition, sending its shares down nearly 5 percent in on Tuesday.
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
While small-cap stocks, such as Endo International plc (NASDAQ:ENDP) with its market cap of US$1.53B, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
Generic drugmaker Endo International Plc reported a smaller fourth-quarter loss on Tuesday, due to lower asset impairment charges. Net loss attributable to shareholders narrowed to $368.4 million, or $1.65 ...
DUBLIN , Feb. 27, 2018 /PRNewswire/ -- Fourth-quarter 2017 revenues of $769 million ; Full-year 2017 revenues of $3,469 million Fourth-quarter 2017 Sterile Injectables revenues increased 16 percent to ...
Endo International is nearing a settlement to resolve the lawsuits filed against the company by users of its drugs designed to increase testosterone levels in men. “The parties are negotiating the terms of a potential settlement, subject to certain contingencies and conditions,” said Endo spokeswoman Health Zoumas Lubeski. Endo, which is based in Dublin, Ireland, and has its U.S. headquarters in Malvern, was among a handful of pharmaceutical companies — a list that also includes Abbvie and GlaxoSmithKline — sued by thousands of users of testosterone-boosting programs by patients alleging the drug makers did not properly disclose health risks associated with taking such products.
Endo Pharmaceuticals Inc. and GlaxoSmithKline LLC agreed to settle lawsuits accusing the drugmakers of hiding the health risks of a testosterone-boosting drug marketed to middle-aged men, according to ...